We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Liquid Biopsy Lung Cancer Screening Method Developed

By LabMedica International staff writers
Posted on 09 Apr 2020
Genomic blood tests for cancer screening and early detection have become the focus of attention in the molecular diagnostic space, though most activity so far has been either toward pan-cancer screening tools, or in a few other specific tumor types like colorectal cancer, where tests hope to vie against colonoscopy and existing stool-based methods.

Radiologic screening of high-risk adults reduces lung-cancer-related mortality; however, a small minority of eligible individuals undergo such screening in the USA. More...
The availability of blood-based tests could increase screening uptake. A novel circulating tumor DNA (ctDNA) detection assay has been developed that could help physicians screen individuals at risk for lung cancer.

A large team of scientists at Stanford University (Stanford, CA, USA) and their colleagues have described a method, called Lung-CLiP (lung cancer likelihood in plasma), involves targeted sequencing of cell-free DNA (cfDNA) from plasma and matched white blood cell DNA to assess copy number and single nucleotide variants, coupled with a machine learning model that estimates the probability that a cfDNA mutation is tumor-derived. The estimate is based on biological and technical features specific to each variant, such as background frequency, cfDNA fragment size, the gene affected, and the likelihood of clonal hematopoiesis.

The team first trained and optimized Lung-CLiP in an initial sample of 104 patients with early stage non-small cell lung cancer and 56 matched controls. When they then applied it to an independent set of validation samples (46 cases and 48 risk-matched controls), the test was able to discriminate early-stage lung cancer patients with sensitivity and specificity levels that the authors believe suggest a significant benefit to the clinic: depending on where they set their specificity threshold, the method could achieve 63% sensitivity for stage I tumors and up to 75% sensitivity in detecting patients with stage III disease. Setting their cutoff at 98% specificity, the investigators found that Lung-CLiP detected 41% of patients with stage I disease, 54% of patients with stage II disease and 67% of those with stage III disease.

Ash Alizadeh, MD, PhD, an associate professor of Oncology and a senior author of the study, said, “Lung-CLiP could help increase the rate of early detection. This would be analogous to how stool-based testing proposes to improve screening for colorectal cancers, especially in populations where adoption of colonoscopy is lower than currently recommended.” The study was published on March 25, 2020 in the journal Nature.

Related Links:
Stanford University


Gold Member
Troponin T QC
Troponin T Quality Control
3-Part Differential Hematology Analyzer
Swelab Alfa Plus Sampler
New
Silver Member
Fibrinolysis Assay
HemosIL Fibrinolysis Assay Panel
New
Chlamydia Trachomatis Test
Aptima Chlamydia Trachomatis Assay
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: A simple blood test could replace surgical biopsies for early detecion of heart transplant rejection (Photo courtesy of Shutterstock)

Blood Test Detects Organ Rejection in Heart Transplant Patients

Following a heart transplant, patients are required to undergo surgical biopsies so that physicians can assess the possibility of organ rejection. Rejection happens when the recipient’s immune system identifies... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.